Dermata Therapeutics, Inc.
DRMA
$6.45
$0.2183.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -16.14% | 8.49% | 18.24% | 21.05% | 14.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.90% | 55.60% | 53.08% | 23.89% | -2.16% |
| Operating Income | -29.90% | -55.60% | -53.08% | -23.89% | 2.16% |
| Income Before Tax | -31.86% | -57.64% | -53.75% | -22.16% | 4.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -31.86% | -57.64% | -53.75% | -22.16% | 4.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.86% | -57.64% | -53.75% | -22.16% | 4.15% |
| EBIT | -29.90% | -55.60% | -53.08% | -23.89% | 2.16% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 75.73% | 41.33% | -13.90% | -175.65% | -- |
| Normalized Basic EPS | 75.73% | 41.33% | -13.90% | -175.65% | -- |
| EPS Diluted | 75.73% | 41.33% | -13.90% | -175.65% | -- |
| Normalized Diluted EPS | 75.73% | 41.33% | -13.90% | -175.65% | -- |
| Average Basic Shares Outstanding | 835.89% | 757.36% | 662.34% | 818.89% | -- |
| Average Diluted Shares Outstanding | 835.89% | 757.36% | 662.34% | 818.89% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |